Bahri, Priya http://orcid.org/0000-0002-7798-6117
Bowring, Geoffrey
Edwards, Brian D.
Anton, Christopher
Aronson, Jeffrey K.
Caro-Rojas, Angela
Hugman, Bruce P. J.
Mol, Peter G.
Trifirò, Gianluca
Ilic, Katarina
Daghfous, Riadh
Fermont, Irene
Furlan, Giovanni
Gaissmaier, Wolfgang
Geer, Mohammad Ishaq
Hartigan-Go, Kenneth Y.
Houÿez, François
Neth, Hansjörg
Norgela, Gediminas
Oppamayun, Yaowares
Raynor, D. K. Theo
Bouhlel, Mehdi
Santoro, Federica
Sultana, Janet
Article History
Accepted: 1 March 2023
First Online: 23 May 2023
Declarations
:
: No sources of funding were used in the preparation of this article.
: The views expressed in this report are the authors’ personal views and may not be understood or quoted as being made on behalf of or reflecting the position of the employing organisations. Priya Bahri’s activity as the ISoP CommSIG Coordinator is pro bono in her personal capacity and time, outside the working hours of the European Medicines Agency as her employing organisation. She abstains from contributing to ISoP comments in response to public consultations of EU policies and projects.Priya Bahri, Geoffrey Bowring, Brian D. Edwards<sub>,</sub> Angela Caro-Rojas, Bruce P.J. Hugman, Peter G. Mol, Katarina Ilic, Riadh Daghfous, Irene Fermont, Wolfgang Gaissmaier, Mohammad Ishaq Geer, François Houÿez, Hansjörg Neth, Gediminas Norgela, Yaowares Oppamayun, Mehdi Bouhlel, Federica Santoro and Janet Sultana have no conflicts of interests to declare. Christopher Anton receives an annual grant from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and owns shares in AstraZeneca, GlaxoSmithKline, BioNTech, Smith and Nephew, and Advanced Oncotherapy. Jeffrey K. Aronson has written articles and edited textbooks and has given medicolegal advice about adverse drug reactions. Giovanni Furlan is an employee of Pfizer s.r.l. and owns stocks in Pfizer, as well as other pharmaceutical companies through exchange traded funds. Kenneth Hartigan-Go declares that since 2018 he has been a respondent in legal cases in the Philippines involving the vaccine product Dengvaxia. D.K. Theo Raynor is co-founder and academic advisor to Luto Research, which was a spinout company of the University of Leeds, and develops, refines and tests health information; he is also co-chair of the Patient Safety Communication Advisory Panel at Bayer AG, Berlin. Gianluca Trifirò attended seminars and advisory boards funded by pharmaceutical companies on topics not related to the contents of this article, as head of a pharmacoepidemiological team at the University of Messina (until October 2020), and now of the academic spinoff INSPIRE, coordinated some observational studies and a Master’s programme, which received unconditional grants from several pharmaceutical companies; in addition, he participated in advisory boards that have been sponsored by several pharmaceutical companies; all these activities are not related to the topic of this article.
: Not applicable.
: Not applicable (as this is not a study report).
: Not applicable (as this is not a study report).
: The article is based on presentations at the ISoP events and other referenced materials, as well as personal notes taken by Priya Bahri and Ulrich Hagemann during the referenced sessions and meetings.
: Not applicable.
: The data and materials for this article were compiled by PB as the ISoP CommSIG Coordinator, and the article was drafted by PB and GB. Contributions to the content were made as follows: CA, JKA, PB, AC-R, BDE, IF, MIG, FH, BPJH, PGM, HN, YO and DKR as leads and presenters of referenced abstracts/oral presentations for sessions on risk communication during ISoP annual meetings underpinned by slides and/or scripts; MB, FS and JS as leads of referenced abstracts for sessions on risk communication during ISoP annual meetings; RD, GN and GT as abstract co-authors and presenters for sessions on risk communication during ISoP annual meetings, as referenced; PB, BDE and KI as session chairs for sessions on risk communication during ISoP annual meetings, as referenced; GB and PB through reviewing and selecting the poster abstracts for Appendix 2; WG as an additional expert who provided draft text for the article; and CA, JKA, AC-R, BDE, GF, KYH, BPJH, KI, PGM and GT through comments on the draft article. All authors reviewed and approved the final version of this article.
Free to read: This content has been made available to all.